Literature DB >> 326634

Escherichia coli serotypes throughout the gastrointestinal tract of patients with intestinal disorders.

S Tabaqchali, A Howard, C H Teoh-Chan, K A Bettelheim, S L Gorbach.   

Abstract

The O and H serotypes of Escherichia coli that were present along the entire length of the gastrointestinal tract of patients with small intestinal bacterial overgrowth were studied. Multiple sero- and biotypes were represented, although usually a single serotype predominated in each patient. In a number of cases the different O:H serotypes were antigenically related indicating that antigenic degradation was occurring. The serotypes isolated from the stomach and small intestine were represented in the faeces. In general, within the limitations of this study, there appears to be a stable ecosystem in each patient and it may require specific oral antibiotics to alter it.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326634      PMCID: PMC1411485          DOI: 10.1136/gut.18.5.351

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Fate of ingested Escherichia coli in normal persons.

Authors:  E M Cooke; I G Hettiaratchy; A C Buck
Journal:  J Med Microbiol       Date:  1972-08       Impact factor: 2.472

2.  Animal sources of common serotypes of Escherichia coli in the food of hospital patients. Possible significance in urinary-tract infections.

Authors:  R A Shooter; E M Cooke; S A Rousseau; A L Breaden
Journal:  Lancet       Date:  1970-08-01       Impact factor: 79.321

3.  A study of Escherichia coli isolated from chronic urinary infection.

Authors:  K A Bettelheim; J Taylor
Journal:  J Med Microbiol       Date:  1969-08       Impact factor: 2.472

4.  Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons.

Authors:  B S Drasar; M Shiner; G M McLeod
Journal:  Gastroenterology       Date:  1969-01       Impact factor: 22.682

5.  Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora.

Authors:  S L Gorbach; A G Plaut; L Nahas; L Weinstein; G Spanknebel; R Levitan
Journal:  Gastroenterology       Date:  1967-12       Impact factor: 22.682

6.  A rapid method of identifying Escherichia coli H antigens.

Authors:  M E Chandler; K A Bettelheim
Journal:  Zentralbl Bakteriol Orig A       Date:  1974

7.  Bacteria, bile, and the small bowel.

Authors:  S L Gorbach; S Tabaqchali
Journal:  Gut       Date:  1969-12       Impact factor: 23.059

8.  Spread of Escherichia coli colonizing newborn babies and their mothers.

Authors:  K A Bettelheim; C H Teoh-Chan; M E Chandler; S M O'Farrell; L Rahamim; E J Shaw; R A Shooter
Journal:  J Hyg (Lond)       Date:  1974-12

9.  Changing faecal population of Escherichia coli in hospital medical patients.

Authors:  E M Cooke; S Ewins; R A Shooter
Journal:  Br Med J       Date:  1969-12-06

10.  Further studies of Escherichia coli in babies after normal delivery.

Authors:  K A Bettelheim; C H Teoh-Chan; M E Chandler; S M O'Farrell; L Rahamin; E J Shaw; R A Shooter
Journal:  J Hyg (Lond)       Date:  1974-10
View more
  4 in total

1.  Smoking, humoral immunity, and ulcerative colitis.

Authors:  E D Srivastava; J R Barton; S O'Mahony; D I Phillips; G T Williams; N Matthews; A Ferguson; J Rhodes
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Escherichia coli antibodies in patients with inflammatory bowel disease.

Authors:  S Tabaqchali; D P O'Donoghue; K A Bettelheim
Journal:  Gut       Date:  1978-02       Impact factor: 23.059

3.  Adhesion of commensal bacteria to the large intestine wall in humans.

Authors:  C L Hartley; C S Neumann; M H Richmond
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

4.  Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome.

Authors:  Aiysha Thompson; Dilruba Meah; Nadia Ahmed; Rebecca Conniff-Jenkins; Emma Chileshe; Chris O Phillips; Tim C Claypole; Dan W Forman; Paula E Row
Journal:  BMC Complement Altern Med       Date:  2013-11-28       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.